Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) reported Q2 EPS of ($0.88), $0.04 better than the analyst estimate of ($0.92). Revenue for the quarter came in at $40.81 million versus the consensus estimate of $32.36 million.

For earnings history and earnings-related data on Tarsus Pharmaceuticals, Inc. (TARS) click here.